Drugs / Compound Ciwujia Granules
Compound Ciwujia Granules
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT07306494 | Jan 2026 → Apr 2028 expected | insomnia | Hui Zhu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07085143 | Oct 2025 → Jun 2026 overdue | major depressive disorder | Shanghai Mental Health Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06245642 | Mar 2024 → Jan 2025 | myalgic encephalomeyelitis/chronic fatigue syndrome | Heilongjiang Quanle Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07050563 | Oct 2025 → Sep 2028 expected | cancer | Shanghai Municipal Hospital of Traditional Chinese Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Ciwujia Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245642 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a TCM regimen for cancer symptom clusters (CSCs)” NCT07050563 ↗ |
| Route | Oral | “Experimental group: Basic treatment + Compound Ciwujia Granules + Guipi Granules simulator orally for 6 weeks; Positive drug control group: basic treatment + Guipi Granules +...” NCT06245642 ↗ |